Invention Grant
US09555033B2 Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
有权
鉴定LKB1突变作为TOR激酶抑制剂敏感性的预测生物标志物
- Patent Title: Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
- Patent Title (中): 鉴定LKB1突变作为TOR激酶抑制剂敏感性的预测生物标志物
-
Application No.: US13020031Application Date: 2011-02-03
-
Publication No.: US09555033B2Publication Date: 2017-01-31
- Inventor: Rajesh Chopra , Yuhong Ning , Sabita Sankar , Shuichan Xu , Weiming Xu
- Applicant: Rajesh Chopra , Yuhong Ning , Sabita Sankar , Shuichan Xu , Weiming Xu
- Applicant Address: US CA San Diego
- Assignee: Signal Pharmaceuticals, LLC
- Current Assignee: Signal Pharmaceuticals, LLC
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: A61K31/5383
- IPC: A61K31/5383 ; A61K31/519 ; A61K31/155 ; A61K31/4985 ; A61K31/7004
Abstract:
Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.
Public/Granted literature
- US20110257167A1 IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS Public/Granted day:2011-10-20
Information query
IPC分类:
